Jushi Holdings Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CHANGES IN (DEFICIT) EQUITY

CONSOLIDATED STATEMENTS OF CHANGES IN (DEFICIT) EQUITY - USD ($) $ in Thousands	Total	Grover Beach	Nature’s Remedy	Apothecarium	NuLeaf	NuLeaf contingent consideration	Common Stock Super Voting Shares	Common Stock Multiple Voting Shares	Common Stock Subordinate Voting Shares	Common Stock Subordinate Voting Shares Grover Beach	Common Stock Subordinate Voting Shares Nature’s Remedy	Common Stock Subordinate Voting Shares Apothecarium	Common Stock Subordinate Voting Shares NuLeaf	Common Stock Subordinate Voting Shares NuLeaf contingent consideration	Total Jushi Shareholders' Equity	Total Jushi Shareholders' Equity Grover Beach	Total Jushi Shareholders' Equity Nature’s Remedy	Total Jushi Shareholders' Equity Apothecarium	Total Jushi Shareholders' Equity NuLeaf	Total Jushi Shareholders' Equity NuLeaf contingent consideration	Paid-In Capital	Paid-In Capital Grover Beach	Paid-In Capital Nature’s Remedy	Paid-In Capital Apothecarium	Paid-In Capital NuLeaf	Paid-In Capital NuLeaf contingent consideration	Accumulated Deficit	Non-Controlling Interests
Balance at beginning of period (in shares) at Dec. 31, 2020							149,000	4,000,000	132,396,064
Balance at beginning of period at Dec. 31, 2020	$ 2,423														$ (524)						$ 262,145						$ (262,669)	$ 2,947
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Offerings (in shares)									13,685,000
Offerings	85,660														85,660						85,660
Purchase of non-controlling interests (in shares)									500,000
Purchase of non-controlling interests - Agape	0														1,562						1,562							(1,562)
Shares issued for acquisition (in shares)										49,348	8,700,000
Shares issued for acquisition		$ 368	$ 35,670													$ 368	$ 35,670					$ 368	$ 35,670
Shares issued upon conversion of debt at maturity (in shares)							(149,000)	(4,000,000)	18,900,000
Shares issued for restricted stock grants (in shares)									65,398
Shares issued upon exercise of warrants (in shares)									8,667,173
Shares issued upon exercise of warrants	24,676														24,676						24,676
Shares issued upon exercise of stock options (in shares)									216,133
Shares issued upon exercise of stock options	171														171						171
Share-based compensation (including related parties)	14,506														14,506						14,506
Settlement of promissory notes due from related parties (in shares)									(471,757)
Settlement of promissory notes due from related parties	30														30						30
Net income (loss)	17,479														20,251												20,251	(2,772)
Balance at end of period (in shares) at Dec. 31, 2021							0	0	182,707,359
Balance at end of period at Dec. 31, 2021	180,983														182,370						424,788						(242,418)	(1,387)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Offerings (in shares)									3,717,392
Offerings	13,680														13,680						13,680
Shares issued for acquisition (in shares)												527,704	5,551,264	114,416
Shares issued for acquisition				$ 1,594	$ 15,102	$ 317												$ 1,594	$ 15,102	$ 317				$ 1,594	$ 15,102	$ 317
Shares issued upon conversion of debt at maturity (in shares)									910,000
Shares issued upon exercise of warrants (in shares)									3,176,601
Shares issued upon exercise of warrants	$ 10,578														10,578						10,578
Shares issued upon exercise of stock options (in shares)	324,998								121,976
Shares issued upon exercise of stock options	$ 26														26						26
Share-based compensation (including related parties)	23,073														23,073						23,073
Net income (loss)	(202,324)														(202,324)												(202,324)
Shares issued upon conversion of debt at maturity	2,412														2,412						2,412
Shares canceled upon forfeiture of non-vested restricted stock (in shares)									(140,340)
Collection of note receivable from employee shareholder	450														450						450
Balance at end of period (in shares) at Dec. 31, 2022							0	0	196,686,372
Balance at end of period at Dec. 31, 2022	45,891														47,278						492,020						(444,742)	(1,387)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation (including related parties)	8,092														8,092						8,092
Net income (loss)	(65,102)														(65,102)												(65,102)
Shares canceled upon forfeiture of non-vested restricted stock (in shares)									(54,774)
Modification and reclassification of warrants	3,391														3,391						3,391
Cashless exercise of options	(282)														(282)						(282)
Issuance of warrants	391														391						391
Balance at end of period (in shares) at Dec. 31, 2023							0	0	196,631,598
Balance at end of period at Dec. 31, 2023	$ (7,619)														$ (6,232)						$ 503,612						$ (509,844)	$ (1,387)